Inflation and the Covid-19 pandemic have put pharmaceutical productivity front and center in recent years. Thus, drug companies are under mounting pressure to prove that new treatments are safe and ...
In this free webinar, gain insight into how model-informed drug development uses early PK/PD data, extrapolation and simulation to enable earlier, regulator-ready pediatric dose selection with fewer ...
Attendees from 57 Countries Spend Two Days Focused on Advancing Model-Informed Drug Development We focus our Environmental, Social, and Governance (ESG) efforts where we can have the most positive ...
RESEARCH TRIANGLE PARK, N.C.--(BUSINESS WIRE)--Simulations Plus, Inc. (Nasdaq: SLP) (“Simulations Plus” or the “Company”), a global leader in model-informed and AI-accelerated drug development that ...
Simulations Plus is a specialized in silico software-and-services platform. They help with model-informed, non-animal drug development. SLP’s services help across discovery, development, and clinical ...
In a recent exclusive interview, Fierce Biotech’s Chris Hayden sat down with Alex MacDonald, Vice President of Model-Informed Drug Development at Allucent, to explore the impact of Project Optimus, an ...
Designed to help biopharmaceutical teams focus on the most promising drug candidates, EVA generates clinical predictions with up to twice the performance of current industry standards.Paris, February ...
NIEHS' collaboration with Simulations Plus is part of a national effort to modernize chemical safety assessment through AI-powered new approach methodologies and will continue the application of the ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results